The GLP-1 Saga Is Just Getting Started
Derek Lowe, Science Magazine Keeping up with the GLP-1 area is a full time job by itself. First off, you have the recent development that these drugs are no longer considered to officially…
Forget Ozempic, scientists find a microbe that can work like a natural alternative to popular diabetes and weight loss drug
Researchers in China have found a gut microbe, Bacteroides vulgatus, that may regulate blood sugar. The microbe and its metabolites can stimulate GLP-1 secretion. GLP-1 is a hormone that controls blood sugar and fullness. The study showed that increasing this microbe in mice can help. This discovery may offer a natural alternative to drugs like […]
GLP-1 RA Use for Obesity Soars Among Nondiabetic US Adults
Between 2018 and 2022, GLP-1 RA use surged among US adults without diabetes, yet adoption remained modest. Medscape Medical News
FDA Accepts Filing Application for Oral Semaglutide 25 mg, Which If Approved, Would Be The First Oral GLP-1 Treatment for Obesity
PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ — Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy®…
Review Article – GLP-1-Based Therapies for Diabetes, Obesity and Beyond
by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8. Epub ahead of print. PMID: 40281304. This review article discusses GLP-1-based therapies, highlighting their effectiveness for managing type 2 diabetes and obesity, including well-known drugs like semaglutide and tirzepatide. The text details the evolution […]
‘Ozempic Mouth,’ ‘Feet’ Are Latest Names For GLP-1 Med Side Effects
You may have heard of “Ozempic face” and “Ozempic butt.” Well, now there’s “Ozempic mouth” and “Ozempic feet” to describe more effects of GLP-1 receptor agonists.
New GLP-1 Survey Finds Users Cutting Restaurant Spend
New GLP-1 Survey Finds Users Cutting Restaurant Spend Last week’s GLP-1 headlines included Novo Nordisk partnering with telehealth platforms Hims & Hers, LifeMD, and Ro to offer its weight-loss drug Wegovy directly to consumers at substantial discounts, aiming to improve affordability and access. Meanwhile, Eli Lilly reported robust demand for its rival anti-obesity medication, Mounjaro. […]